Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice

查看全文 作　　者：Mingqing [1,2,3]Lu;Kunpeng [2,3]Liu;Yun [4]Peng;Zhe [1,3]Ding;Yingwen [1,3]Li;Alexander [1,3]Tendu;Xue [2]Hu;Ge [4]Gao;Weiwei [2,3]Guo;Hang [4]Liu;Juhong [2,3]Rao;Jiaxuan [2,3]Zhao;Miaoyu [4]Chen;Zhiming [4]Yuan;Gary [1]Wong;Chao [2]Shan;Yanfeng [4]Yao;Jiaming [1]Lan 机构地区：[1]CAS Key Laboratory of Molecular Virology&Immunology,Institut Pasteur of Shanghai,Chinese Academy of Sciences,Shanghai,200031,China;[2]State Key Laboratory of Virology,Chinese Academy of Sciences,Wuhan,430071,China;[3]University of Chinese Academy of Sciences,Beijing,100049,China;[4]Center for Biosafety Mega-Science,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China 出　　处：《Virologica Sinica》索引2022年第37卷第4期,共10页 基　　金：the National Natural Science Foundation of China(No.32070933 to J.M.Lan and Y.F.Yao);the Natural Science Foundation of Shanghai(No.20ZR1463900 to J.M.Lan);financially the STS regional key project(KFJ-STS-QYZD-2021-12-001 to Z.M.Yuan and C.Shan)from Chinese Academy of Sciences;National Key R&D Program of China 2021YFE0201900 to C.Shan and 2021YFC0863300 to Z.M.Yuan and C.Shan;the National Key R&D Program of China(No.2021YFC0863400);funding from Institut Pasteur,Fondation Merieux and the Chinese Academy of Sciences to G.W。 摘　　要：SARS-CoV-2 infection is a global public health threat.Vaccines are considered amongst the most important tools to control the SARS-CoV-2 pandemic.As expected,deaths from SARS-CoV-2 infection have dropped dramatically with widespread vaccination.However,there are concerns over the duration of vaccine-induced protection,as well as their effectiveness against emerging variants of concern.Here,we constructed a recombinant chimpanzee adenovirus vectored vaccine expressing the full-length spike of SARS-CoV-2(Ad C68-S).Rapid and high levels of humoral and cellular immune responses were observed after immunization of C57BL/6J mice with one or two doses of Ad C68-S.Notably,neutralizing antibodies were observed up to at least six months after vaccination,without substantial decline.Single or double doses Ad C68-S immunization resulted in lower viral loads in lungs of mice against SARS-CoV-2 challenge both in the short term(21 days)and long-term(6 months).Histopathological examination of Ad C68-S immunized mice lungs showed mild histological abnormalities after SARS-CoV-2 infection.Taken together,this study demonstrates the efficacy and durability of the Ad C68-S vaccine and constitutes a promising candidate for clinical evaluation. 关 键 词：SARS-CoV-2 VACCINE Chimpanzee adenovirus vector Neutralizing antibodies Long-term protection